Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    "Collecting duct carcinoma"
Show Display Options
Rank Status Study
1 Recruiting Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma
Condition: Renal Cell Carcinoma
Intervention: Drug: sorafenib+gemcitabine+cisplatin
2 Active, not recruiting Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
Conditions: Renal Cell Cancer;   Kidney Cancer
Intervention: Drug: Sunitinib Malate
3 Active, not recruiting Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
Condition: Kidney Cancer
Interventions: Drug: Everolimus;   Drug: Sunitinib

Indicates status has not been verified in more than two years